Anticancer carrier-linked prodrugs in clinical trials

Author： Kratz Felix Abu Ajaj Khalid Warnecke André

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.7, 2007-07, pp. : 1037-1058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial [Hot Topic: Anticancer Macromolecular Prodrugs in Clinical Trials - an Update (Guest Editor: Felix Kratz)]

Current Bioactive Compounds, Vol. 7, Iss. 1, 2011-01 ,pp. : 1-2

Bentham Science Publishers

Access to resources Recommend Favorite

Marine-derived anticancer agents in clinical trials

By Schwartsmann Gilberto da Rocha Adriana Brondani Mattei Jane Lopes RafaelMartins

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1367-1383

Informa Healthcare

Access to resources Recommend Favorite

Prodrugs in Photodynamic Anticancer Therapy

Current Pharmaceutical Design, Vol. 17, Iss. 32, 2011-11 ,pp. : 3548-3559

Bentham Science Publishers

Access to resources Recommend Favorite

Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

Current Pharmaceutical Design, Vol. 18, Iss. 20, 2012-07 ,pp. : 2921-2935

Bentham Science Publishers

Access to resources Recommend Favorite

Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials

Current Drug Metabolism, Vol. 14, Iss. 5, 2013-06 ,pp. : 583-604

Bentham Science Publishers

Access to resources Recommend Favorite